Results 121 to 130 of about 28,326 (256)

Postoperative ctDNA monitoring: a canary in a coalmine

Annals of Oncology, 2021
Lumish M, Tarazona N, Janjigian Y
openaire   +3 more sources

ctDNA SNORD3F Hypermethylation is a Prognostic Indicator in EGFR-TKI-Treated Advanced Non-Small Cell Lung Cancer

Cancer Management and Research
Bin Liu,* Bingtian Zhao,* Yan Yin, Yan Jiang, Xue Feng, Lei Wang, Liang Zhai, Guangxin Liu, Dongsheng Shi, Jianwen Qin Department of Respiratory and Critical Medicine, Tianjin Chest Hospital, Tianjin, People’s Republic of China*These authors ...
Liu B, Zhao B, Yin Y, Jiang Y, Feng X, Wang L, Zhai L, Liu G, Shi D, Qin J   +9 more
doaj  

Clinical specificity for each Target Selector ctDNA assay.

, 2019
Clinical specificity of each Target Selector ctDNA assay was validated on DNA extracted from 4ml of healthy donor plasma samples. For each of Target Selector ctDNA assay, no mutation was detected from 20 healthy donors, suggesting >99% clinical ...
Timothy T. Lu (7461308), Anh Pham (2630491), Jeffrey Chen (1569064), Manisha Patel (114605), Tony Daher (7461317), Cecile Rose T. Vibat (7461311), Jason C. Poole (7461302), Errin Samuelsz (7461314), Veena M. Singh (7461320), Shan-Fu Wu (7461305), Lyle J. Arnold (7461323)   +10 more
core   +1 more source

Parallel Liquid Biopsy Analysis of miR‐371a‐3p and Cell‐Free DNA in an Unselected Cohort of Patients With Testicular Germ Cell Tumors

Andrology, EarlyView.
ABSTRACT Background Despite robust data showing strong potential to improve diagnosis and disease monitoring in testicular germ cell tumors (TGCTs), miR‐371a‐3p testing has not yet been implemented in routine clinical practice. Cell‐free DNA (cfDNA) represents another promising liquid biopsy biomarker that may provide complementary molecular ...
Laura Matouskova, Romy Kralova, Eva Parobkova, Violeta Bakardjieva‐Mihaylova, Martina Zwyrtkova, Karolina Skvarova Kramarzova, Ludmila Boublikova   +6 more
wiley   +1 more source

ADN tumoral circulante en pacientes con cáncer: perspectivas desde el laboratorio clínico

Advances in Laboratory Medicine
El análisis de ADN tumoral circulante (ctDNA) es un método no invasivo de gran relevancia para la caracterización molecular de los tumores sólidos, que aporta información valiosa sobre el perfil genético del cáncer. Actualmente, el análisis de mutaciones
Illana Francisco J., Fernández-Galán Esther, Muñoz-Bravo José Luis, Amado Laura Valiña, García Martín Carme, González-Fernández Carolina, Miró-Cañís Sílvia, Trapé Jaume, Martínez-Peinado Antonio, Filella Xavier, González Alvaro, Barco Sánchez Antonio, Díaz-Lagares Angel,   +13 more
doaj   +1 more source

Surveillance After Pelvic Exenteration: A Systematic Review of Oncological and Functional Follow‐Up

ANZ Journal of Surgery, EarlyView.
ABSTRACT Background Surveillance following cancer surgery with curative intent serves the purpose of permitting early detection of recurrent disease in addition to monitoring and management of post‐resection functional sequelae. Although recommendations exist for most primary cancers, in the context of radical or re‐operative surgery such as pelvic ...
Adrian Hang Yue Siu, Konrad Joseph, Daniel Steffens, Sharon Carey, Michael Solomon, Cherry Koh   +5 more
wiley   +1 more source

Appropriate Duration of First-line Immunotherapy for 
Advanced NSCLC and Predictive Factors

Chinese Journal of Lung Cancer
First-line immunotherapy for advanced non-small cell lung cancer (NSCLC) shows significant survival benefits in patients without driver mutations, but the optimal duration of treatment remains controversial. Some studies support limiting immunotherapy to
Yue YIN, Xiaotong GUO, Jing AI, Jibo YUE, Lili DENG   +4 more
doaj   +1 more source

Baseline ctDNA detection using NGS.

, 2016
On the left, the figure shows EGFR, KRAS, and BRAF mutation testing with dPCR and NGS. On the right, the figure shows the 105 patients eligible for baseline ctDNA NGS testing, among whom 74 were positive.
Eleonora Zonta (3153192), Audrey Didelot (3153195), Constance Thibault (3603650), Yves Rozenholc (3603653), Elizabeth Fabre (187892), Camille Lours (3603656), Nicolas Pécuchet (3153186), Pierre Combe (3603659), Pierre Laurent-Puig (56604), Laure Gibault (228316), Hélène Blons (187905), Valérie Taly (3153189)   +11 more
core   +1 more source

Minimal residual disease in diffuse large B‐cell lymphoma after first‐line therapy: Defining the continuum from metabolic remission to molecular clearance

British Journal of Haematology, EarlyView.
Summary Response assessment in diffuse large B‐cell lymphoma (DLBCL) has traditionally relied on anatomical and metabolic imaging, with fluorodeoxyglucose positron emission tomography (FDG‐PET)–defined complete metabolic remission representing the principal end‐point of first‐line therapy. However, growing evidence indicates that metabolic control does
Santino Caserta, Enrica Antonia Martino, Ernesto Vigna, Antonella Bruzzese, Mamdouh Skafi, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Maria Eugenia Alvaro, Fortunato Morabito, Massimo Gentile   +12 more
wiley   +1 more source

Clinical complete response as a surrogate for pathological response in bladder cancer: a systematic review and meta‐analysis

BJU International, EarlyView.
Objective To evaluate the concordance between clinical complete response (cCR) and pathological complete response (pCR) in muscle‐invasive bladder cancer (MIBC) to assess the surrogacy and prognostic value of cCR for guiding bladder‐sparing strategies.
Navid Roessler, Marcin Miszczyk, Paolo Gontero, Alessandro Dematteis, Keiichiro Miyajima, Shota Inoue, Katharina Oberneder, Markus von Deimling, Victor M. Schuettfort, Malte W. Vetterlein, Bernadett Szabados, Pawel Rajwa, Pierre I. Karakiewicz, Jeremy Yuen‐Chun Teoh, Margit Fisch, Shahrokh F. Shariat   +15 more
wiley   +1 more source